Surgery and Transcatheter Intervention for Degenerative Mitral Regurgitation in The United States.

OBJECTIVES: We evaluated practice trends and 3-year outcomes of transcatheter edge-to-edge repair (TEER) and surgical repair for degenerative mitral regurgitation (MR) in the U.S.

METHODS: From the Centers for Medicare and Medicaid data (2012-2019), 53,117 mitral valve interventions (surgery or TEER) were performed for degenerative MR, identified by excluding rheumatic and congenital disease, endocarditis, myocardial infarction, cardiomyopathy, and concomitant or prior coronary revascularizations. Median follow-up was 2.9 (interquartile range 1.2-5.1) years. Endpoints were three-year survival, stroke, mitral re-interventions, and heart failure readmissions.

RESULTS: Volume of total annual mitral interventions did not significantly change (p=0.18) between 2012-2019. However, surgical cases decreased by a third while TEER increased. Among 27,170 patients (52.5% male, mean age 73.5 years) who underwent TEER (n=7755) or surgical repair (n=19,415), surgical patients were younger (71.8 versus 80.8 years, p<0.001), with less comorbidity and frailty. In 4532 patient pairs matched for age, frailty, and comorbidity, three-year survival after TEER was 65.9% (95% CI 64.3-67.6) and 85.7% (95% CI 84.5-86.9) after surgery (p<0.001). Three years after TEER or surgery, stroke rates were 1.8% (95% CI 1.5-2.2) and 2.0% (95% CI 1.6-2.4) (p=0.49); heart failure readmission rates were 17.8% (95% CI 16.7-18.9) and 11.2% (95% CI 10.3-12.2) (p<0.001); and mitral reintervention rates were 6.1% (95% CI 5.5-6.9) and 1.3% (95% CI 1.0-1.7) (p<0.001), respectively.

CONCLUSIONS: Among Medicare beneficiaries with degenerative MR, an increase in TEER utilization was associated with decreased surgical case volume, while overall mitral interventions volume was unchanged. Randomized trials are needed to better inform treatment choice.